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ABSTRACT
Adult female acne is a chronic inflammatory, immune-mediated disease that affects the
pilosebaceous unit in women in their 20s to 40s, and is considered different from acne vulgaris.
Propionibacterium acnes is recognized by TLR-2, resulting in activation of this receptor and an
inflammatory response through the NFk B pathway. This therapeutic, interventional, open,
randomized, evaluator-blinded and comparative trial included 38 adult women with moderate
facial acne and 10 age-matched controls, all aged between 26 and 44 years. Two treatments were
performed over six months: 15% azelaic acid gel (AA) bid (n D 18) and oral contraceptive (COC)
drospirenone 3 mg/ethinylestradiol .02 mg (n D 20). Biopsies were taken at baseline (control, lesion,
perilesional) and at the conclusion (lesion and perilesional) of the study to evaluate TLR-2
expression by immunohistochemistry. Lesion count and blind photographic evaluation were used
for efficacy. The groups were homogeneous: 70% of lesions were located in the submandibular
area, 95% of participants had inflammatory lesions; of these, 50% had persistent and 50% had late-
onset acne. The mean ages were 33.7 § 5.5 and 33.1 § 5.3 years (COC and AA group, respectively).
A moderate clinical improvement was observed in both groups. No difference in TLR-2 expression
in the lesion or perilesional areas was observed; however, reduced TLR-2 expression was seen in the
control group. A significant reduction in expression was observed after both treatments, with no
difference between the groups. This finding suggests an anti-inflammatory effect of COCs and AA in
adult female acne, via modulation of the TLR-2 receptor.
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Introduction
Acne vulgaris is a common skin disease in adolescents,
with a prevalence of 80 to 90%. During the previous
20 years, an increase of acne prevalence in adults, par-
ticularly in women over 25 years of age, has been
described.1 The reasons for this are not fully under-
stood; some authors postulate that hormonal factors
related to modern life, increases in the search for der-
matological care, and increased medical attention to
this problem may be involved.2-5 Acne in adult
women may have persisted from adolescence, present
as late onset,6 or recur in adult life after onset during
puberty and a disease-free period.7
Adult female acne is a chronic inflammatory and
immune-mediated disease that affects the piloseba-
ceous unit in active, working women in their 20s to
40s, associated or unassociated with hyperseborrhoea
and alterations in serum sexual hormone concentra-
tions (although the majority show no hormonal
abnormalities). This condition is characterized by
mild or moderate inflammatory lesions that worsen
during the pre-menstrual period in 80% of the women
affected.8 Results from a study of 374 adults with acne
showed that in adult women the lesion distribution
may be similar to that seen in adolescents, or be pre-
dominant in the mandibular and neck regions.9 The
skin of adult women with acne is more sensitive than
that of teenagers and prone to irritation with anti-
acne topical products. Adult acne is experienced as
stressful and negatively impacts quality of life.
Affected women frequently present with a severe skin-
picking habit, which results in post-inflammatory
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hyperpigmentation and scarring. This disease is highly
refractory to treatment, with frequent recurrences.8-11
Evidence supports the role of inflammation in all
stages of acne, including subclinically and prior to com-
edo formation.12,13 The underlying pathways are com-
plex and incompletely elucidated, but may involve
Propionibacterium acnes (P. acnes) and inflammatory
mediators and their receptors, including cytokines,
defensins, peptidases, sebum lipids, and neuropeptides.14
The toll-like receptors (TLRs) are trans-membrane
receptors related to the innate immune response. They
are present in immune, epithelial and endothelial cells,
and are involved in the pathogenesis of many dermato-
ses.15,16 The sebaceous gland is a skin appendage that
expresses many receptors, including TLRs.17 TLR-2 is
expressed in keratinocytes, sebocytes, dendritic and
inflammatory cells, as well as in monocytes and macro-
phages, in acne patients.18,19 It plays a crucial role in
comedogenesis and inflammation via activation of tran-
scriptional nuclear factors, such as nuclear factor kappa
B (NFƙB), through triggering the production of several
cytokines (including IL-1a, IL-8, IL-12) and via activa-
tion of other cells, such as macrophages, natural-killer
(NK) and neutrophils.20,21 Additionally, the adaptive
immune response is stimulated.15,16 Several in vivo and
in vitro studies have demonstrated that P. acnes exhib-
its PAMPs (pathogen associated molecular patterns)
that are recognized by TLR-2, which leads to over-
expression and to an inflammatory response.20,22-25 It
is possible to investigate the expression of TLR-2 in
skin cells using rabbit polyclonal antibodies.24 TLRs
can also up-regulate the production of microorganism
peptides, such as b defensins 1 and 2, by epithelial
cells.16
Adult female acne usually requires a specific thera-
peutic approach.26 Hormonal therapy with combined
oral contraceptives (COCs) may be considered the
first line of treatment when there are no contraindica-
tions and no desire for pregnancy.27,28 These hor-
mones decrease the liberation of gonadotrophins,
control androgen production, block androgenic recep-
tors and reduce free testosterone by increasing sexual
binding hormone globulins (SHBG) secretion by the
liver.29-31 This is a safe and effective therapeutic option
for women with or without hormonal abnormalities,
including hyperandrogenism caused by polycystic
ovary syndrome (PCOS).27 A systematic review pub-
lished by the Cochrane Library that analysed compar-
ative studies about the use of various COCs for acne
concluded that they were effective in the reduction of
inflammatory and non-inflammatory lesions, with a
mean reduction of 60% in the lesion count, with no
difference seen between different combinations.32 The
side effects of this treatment included nausea, head-
ache, breast pain, spotting and decreased libido.31,32 In
addition tothe reduction in acne, the COCs exert a
protection against ovarian and endometrial cancer,
and reduce dysmenorrhoea, anaemia (caused by iron
deficiency) and the risk of inflammatory bowel dis-
ease.31 Concerning the risk of venous thromboembo-
lism, the incidence is low in young women and there
is a small increase (.05% to .1%) related to COC use.33
Nevertheless, the risk of a thrombotic event after
delivery is .5%, and during pregnancy is .1%.34 The
indication of COC therefore requires a detailed history
including contraindications such as smoking and a
familial history or risk for deep venous thrombosis
and cardiovascular disease.31
Azelaic acid (AA) is a saturated dicarboxylic acid
and is a topical acne treatment option.35,36 It normal-
izes follicular hyperkeratinization, reduces P. acnes
colonization and controls inflammation. This is
related to the activation of the nuclear receptor
PPARg and inhibition of the NF-kB pathway.37,38 AA
used twice daily for six months demonstrates an effi-
cacy similar to .1% adapalene in maintenance treat-
ment of acne in adult women.39 The aim of this study
is to investigate the possible modulation of TLR-2
expression in sebaceous glands by COC or AA in adult
female acne.
Patients and methods
The study design was a therapeutic, interventional,
open, randomized, evaluator-blinded and comparative
trial with parallel groups. The participants were 38
healthy adult women with moderate facial acne and
10 age-matched controls, aged between 26 and
44 years, who were included after protocol approval
by the Institutional Review Board. Informed consent
was obtained from participants. Inclusion criteria
were the presence of facial acne with no other signs or
symptoms of hyperandrogenism. Exclusion criteria
were treatment of acne with oral antibiotics and
COCs (during the previous three months), oral iso-
tretinoin (during the previous two years), topical
products (during the previous three months), and
having a contraindication for COC use. The
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intervention was: At baseline, two 3-mm punch biop-
sies were performed under local anaesthesia from the
submandibular region (inflammatory lesion and per-
ilesional area). A randomization list was obtained
through a computational program to create two treat-
ment groups for a period of six months: AA (n D 18),
who would use 15% AA gel bid, and COC (n D 20),
who would use COC (drospirenone 3 mg/ethinylestra-
diol .02 mg). A 3-mm punch biopsy was also
performed under local anaesthesia from the subman-
dibular region in participants from the control group.
The efficacy parameters included: the lesion count;
clinical evaluation by two independent dermatologists
by comparing baseline and post-treatment photos;
immunohistochemistry using TLR-2 rabbit polyclonal
antibody (Abcam, code ab24192, dilution1/150) fol-
lowed by histomorphometric analysis using the soft-
ware ImageJ 64 (100x one field). The statistical
analysis comprised: Student’s t-test of mean § stan-
dard deviation scores (age, TLR-2 expression),
Fischers exact test (smoking habit, localization of
lesions, photographic evaluation), analysis of variance
(ANOVA) with repeated measures (lesion count,
TLR-2 expression). SPSS version 16.0 (SPSS Inc;
Illinois, EUA) was used. Results were deemed signifi-
cant for a p value of less than 5% (p < .05).
Results
All participants in the COC group completed the study;
in the AA group, four participants dropped out due to
personal reasons. At baseline, the groups were homoge-
neous for all clinical and biographic data, such as smok-
ing habit (90% did not smoke); lesion distribution (70%
in the submandibular region); lesion type (95% inflam-
matory, i.e., moderate acne), acne onset (50% persistent
and 50% late). The mean ages were 33.7 § 5.5 years
(COC group) and 33.1 § 5.3 years (AA group). All
patients showed moderate clinical improvement and no
severe adverse effects were detected.
TLR-2 expression in the sebaceous glands was
observed in sebocytes cytoplasm (Fig. 1). No difference
in acne lesions were observed between the groups at base-
line (p D .266; Fig. 2). A significant difference in TLR-2
expression was seen between lesion and control group at
baseline (p< .001), estimated as 31.0§ 6.4 (95% CI 17.9,
44.0), as well as between the perilesional area and control
group (p < .001), estimated at 27.3 (95% CI 16.3, 38.2;
Figs. 3 and 4). Using the ANOVA with repeated
measures, the treatment groups were homogeneous in
relation to TLR-2 expression at baseline, with no differ-
ence between them; this was also seen for the lesion and
perilesional area. When comparing TLR-2 expression at
baseline and after treatment, no interaction between
group and time was demonstrated (pD .554); the groups
were homogeneous (pD .192). Nevertheless, a time effect
was observed for both groups (p< .001), with a decrease
in TLR-2 expression after six months of either treatment;
there was no difference seen between the treatments
(Fig. 5).
Discussion
Adult female acne is a chronic, multifactorial and recal-
citrant disease. Many researchers consider its clinical
Figure 1. TLR-2 expression in sebocyte cytoplasm in a sebaceous
gland (400x).
Figure 2. TLR-2 expression in sebaceous glands in acne lesions at
baseline (sg-baseline) between the two treatment groups.
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features different to those of acne vulgaris.4,8-10,40,41 New
insights showing that the innate immune response, espe-
cially inflammation, is mediated by TLRs, have contrib-
uted to a better understanding of several acne
treatments.23,42 The prevalence of this disease has varied
in different populational studies, depending on study
design. The majority have been retrospective, for which
the presence of acne is declared by the patient (some-
times by telephone interview), and which may have
introduced a possible overestimation. In contrast, the
frequent use of COCs may lead to an underestimation
of the number of cases.3,8-11 The population of women
included in this study showed a homogenous distribu-
tion of TLR-2 in the two treatment groups (COCs versus
AA), supporting adequate randomization and therefore
a lower risk of bias. The mean age was 33 years, demon-
strating the chronicity of the disease, corroborating pre-
vious studies that showed a higher prevalence between
30 and 40 years of age.3,9 There is no consensus in the
literature about the minimum and maximum age of par-
ticipants in studies concerning adult female acne.10 The
low number of women who smoked may reflect the
results of repeated campaigns in Brazil regarding the
risks of tobacco. The similar prevalence for persistent
and late-onset acne differed from the majority of studies,
which have emphasized the predominance of persistent
acne.8-10 This may be explained by the rigorous exclu-
sion of patients with hirsutism and/or signs of hyperan-
drogenism. The lesions were mostly inflammatory and
located in the lower face (“U” type), according to the
predominant data from the literature.8,10,11,40,41 A recent
study did not confirm this lesion distribution, probably
because 93% of the women presented with comedones
beyond inflammatory lesions.9 In our study, the acne
severity was moderate. It is difficult to compare this
finding with other studies, as the first standardization
for acne severity scoring in female adults was published
in 2016.43 Clinical evaluation, comparing pre- and post-
treatment photos and lesion counts, showed that at least
80% of patients treated with a COC experienced an
improvement greater than 50%, supporting the findings
of previous studies.29,30,32 The group treated with AA
also showed a significant decrease in the presence of
lesions, as has elsewhere been reported.39 The authors
did not expect the complete clearance of lesions since,
according to the study design, the patients only received
monotherapy. A recent study from our group demon-
strated that even a moderate amelioration of acne has a
positive impact on sleep quality and in turn on a wom-
an’s quality of life.44 There is an unquestionable
Figure 3. TLR-2 expression in acne lesions at baseline and in the
control area in sebaceous glands (sg_baseline; mean § standard
deviation).
Figure 4. TLR-2 expression in perilesional areas at baseline and
control areas in sebaceous glands (sg_baseline; mean § standard
deviation).
Figure 5. Reduction of TLR-2 expression in sebaceous glands in
an acne lesion pre- and post-treatment with COC and AA.
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consensus that inflammatory acne needs combined ther-
apy for a satisfactory result.45
Immunohistochemistry here revealed cytoplasmic
expression of TLR-2 in the sebocytes of the infundibular
area of the pilosebaceous unit, with a predominance in
the periphery of sebaceous glands in the acne lesion and
perilesional regions, as have previously been reported.24
An over-expression of TLR-2 in keratinocytes and sebo-
cytes in acne lesions was here observed. The increased
expression in the perilesional area, compared to the con-
trol group, corroborates the hypothesis that inflamma-
tion occurs prior to the development of clinical
lesions.13,21,24 This observation supports the current rec-
ommendation to apply topical anti-acne products to the
entire compromised area, not only on the isolated
lesions.45 In this study, a significant decrease in TLR-2
expression after six months of both treatments was
observed, which was parallel to clinical improvement.
Previous studies have shown modulation of TLR-2 in
keratinocytes in vitro with adapalene,23 as well as in
monocytes with oral isotretinoin.42 No data exists regard-
ing TLR-2 changes induced by AA or COCs in acne
treatment. Therefore, the modulation of TLR-2 may be a
novel anti-acne mechanism of these drugs. The possible
anti-inflammatory effect of COCs associated with a
reduction of androgenic stimulus in the sebaceous glands
may explain their positive effect on the treatment of acne
in women after puberty, even for those with no hormonal
abnormalities.10,27,45 Despite the limitation of sample size
in this study, it was possible to demonstrate the cyto-
plasmic location and distribution of TLR-2 in sebaceous
glands, which was over-expressed in both the lesion and
perilesional areas in the acne group compared to the con-
trol group. Histomorphometric analysis showed a reduc-
tion in TLR-2 expression accompanied by clinical
improvement of acne lesions. This finding may suggest
an anti-inflammatory effect of COCs and AA in adult
female acne. Future studies investigating the treatment of
acne targeting inflammation should aim to determine the
modulation of TLR-2 and TLR-4, as well as cytokines
such as IL-17.46-48
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